Needham Maintains Buy on AtriCure, Raises Price Target to $68
Portfolio Pulse from richadhand@benzinga.com
Needham analyst Mike Matson maintains a 'Buy' rating on AtriCure (NASDAQ:ATRC) and raises the price target from $60 to $68.
July 26, 2023 | 9:49 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Mike Matson maintains a 'Buy' rating on AtriCure and raises the price target from $60 to $68.
The 'Buy' rating maintained by Needham analyst Mike Matson and the increase in price target from $60 to $68 indicates a positive outlook for AtriCure. This could potentially lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100